Ascendis Pharma A/S

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $4.6m $1.5m $10.6m $13.4m $7.0m $7.8m $51.2m $266.7m $363.6m $720.1m
Revenue From Interest $123k $923k $4.0m $10.1m $1.8m $692k $7.4m $16.9m $14.4m $15.3m
Cost of Goods and Services Sold $1.0m $340k $2.3m $3.0m $1.5m $3.5m $12.1m $44.4m $44.3m $94.9m
Gross Profit (derived) $3.6m $1.2m $8.2m $13.4m $7.0m $4.3m $39.0m $222.3m $319.4m $625.2m
Research and development $66.0m $99.6m $140.3m $191.6m $260.9m $295.9m $379.6m $413.5m $307.0m $303.6m
Operating expenses:
Additional Financial Items
Applicable Tax Rate $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Auditors Remuneration For Tax Services ($68.7m) ($124.4m) ($130.5m) ($218.2m) $104k $87k $138k $122k $91k $0
Average Effective Tax Rate ($0) ($0) ($0) ($0) ($0) $0 $0 $0
Depreciation Right of Use Assets $11.0m $11.7m $11.9m $12.3m $12.3m
Finance Income $7.3m $923k $24.7m $17.8m $1.8m $59.7m $52.2m $43.9m $25.6m $114.0m
Impairment Loss Recognised In Profit Or Loss Goodwill $0 $0 $0 $0
Profit Loss Attributable To Owners Of Parent ($68.7m) ($124.4m) ($130.5m) ($218.2m) ($419.0m) ($383.6m) ($583.2m) ($481.4m) ($378.1m) ($228.0m)
Profit Loss Before Tax ($68.7m) ($124.4m) ($130.5m) ($218.2m) ($419.2m) ($383.9m) ($577.8m) ($474.1m) ($373.2m) ($212.7m)
Profit Loss From Operating Activities ($72.9m) ($111.5m) ($154.8m) ($226.7m) ($330.6m) ($451.8m) ($561.8m) ($455.5m) ($278.8m) ($136.3m)
Net Foreign Exchange Loss $3.1m $13.7m $78.9m $27.1m $0
Basic Earnings (Loss) Per Share ($2.58) ($3.68) ($3.17) ($4.69) ($8.28) ($7.00) ($10.40) ($8.55) ($6.53) ($3.76)
Diluted Earnings (Loss) Per Share ($2.58) ($3.68) ($3.17) ($4.69) ($8.28) ($7.00) ($10.40) ($8.55) ($6.53) ($3.76)
Selling, General and Administrative Expense $11.5m $13.5m $25.1m $48.5m $76.7m $160.2m $221.2m $264.4m $291.1m $457.9m
Current Tax Expense (Income) ($227k) ($477k) $394k $234k $219k $367k ($5.4m) ($5.4m) ($3.3m) ($12.6m)
Deferred Tax Expense (Income) ($3.1m)
Deferred Tax Expense (Income) Recognised In Profit Or Loss ($3.3m)
Employee Benefits Expense $23.6m $31.1m $51.3m $90.9m $136.8m $178.4m $214.7m $258.5m $292.5m $376.6m
Expense From Share-Based Payment Transactions With Employees $7.3m $9.7m $19.7m $37.5m $53.2m $66.8m $64.2m $66.7m $95.5m $116.2m
Expense Relating To Short-Term Leases For Which Recognition Exemption Has Been Used $202k $470k $186k $280k $353k $285k ($228.0m)
Finance Costs $3.1m $13.8m $127k $1.2m $80.8m $3.9m $50.5m $44.1m $100.0m $206.7m
Income Tax Expense Continuing Operations ($227k) ($477k) ($394k) ($234k) ($219k) ($367k) $5.4m $7.3m $4.8m $15.4m
Interest Expense $5k $97k $127k $207k $1.9m $3.9m $30.7m $44.1m $65.5m $80.6m
Interest Expense On Lease Liabilities $1.0m $1.6m $3.4m $3.8m $3.6m $3.3m $4.2m
Other Employee Expense $4.2m $4.1m $5.2m
Other Finance Cost $4.3m
Postemployment Benefit Expense Defined Benefit Plans $49k $324k $444k $648k $943k $2.4m $4.2m $4.4m $4.5m $6.9m